Cargando…
mTOR pathway in human cardiac hypertrophy caused by LEOPARD syndrome: a different role compared with animal models?
BACKGROUND: Animal studies suggested that blocking the activation of the mammalian target of rapamycin (mTOR) pathway might be effective to treat cardiac hypertrophy in LEOPARD syndrome (LS) caused by PTPN11 mutations. RESULTS: In the present study, mTOR pathway activity was examined in human myocar...
Autores principales: | Cui, Hao, Song, Lei, Zhu, Changsheng, Zhang, Ce, Tang, Bing, Wang, Shengwei, Wu, Guixin, Zou, Yubao, Huang, Xiaohong, Hui, Rutai, Wang, Shuiyun, Wang, Jizheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854668/ https://www.ncbi.nlm.nih.gov/pubmed/31722741 http://dx.doi.org/10.1186/s13023-019-1204-4 |
Ejemplares similares
-
Mutation profile of FLNC gene and its prognostic relevance in patients with hypertrophic cardiomyopathy
por: Cui, Hao, et al.
Publicado: (2018) -
TNNI3K, a Cardiac-Specific Kinase, Promotes Physiological Cardiac Hypertrophy in Transgenic Mice
por: Wang, Xiaojian, et al.
Publicado: (2013) -
MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1
por: Song, Lei, et al.
Publicado: (2014) -
Associations of myocardial bridging with adverse cardiac events: a meta-analysis of published observational cohort studies involving 4,556 individuals
por: Zhu, Changsheng, et al.
Publicado: (2020) -
Hyperactivation of mTOR and AKT in a cardiac hypertrophy animal model of Friedreich ataxia
por: Tong, Wing-Hang, et al.
Publicado: (2022)